MERIDIAN BIOSCIENCE INC false 0000794172 0000794172 2020-07-28 2020-07-28












Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) July 28, 2020






(Exact Name of Registrant as Specified in Charter)




Ohio   0-14902   31-0888197

(State or Other Jurisdiction

of Incorporation)



File Number)


(IRS Employer

Identification No.)


3471 River Hills Drive

Cincinnati, Ohio


(Address of principal

executive offices)

  (Zip Code)

Registrant’s telephone number, including area code (513) 271-3700

(Former Name or Former Address, if Changed Since Last Report.)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class





Name of each exchange

on which registered

Common Stock, no par value   VIVO   NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17CFR §240.12b-2 of this chapter).

Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act  ☐




Item 5.02.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Effective July 28, 2020, the Board of Directors (“Board”) of Meridian Bioscience, Inc. (“Meridian” or the “Company”) elected Anthony P. Bihl III to the Board to serve as a director effective immediately until the next annual meeting of shareholders.

Mr. Bihl had been Chief Executive Officer and a member of the board of managers of Bioventus, LLC, a company that develops, manufactures and sells products that promote active orthopedic healing, from December 2013 to April 2020. From June 2011 through June 2012, he was Group President American Medical Systems, or AMS, a subsidiary of Endo Pharmaceuticals. Mr. Bihl was President, Chief Executive Officer and a director of AMS from April 2008 until Endo acquired AMS in June 2011. He served as Chief Executive Officer of the Diagnostics Division of Siemens Medical Solutions from January to November 2007, and as President of the Diagnostics Division of Bayer HealthCare from 2004 through 2006. Prior to that, Mr. Bihl served in a number of operations and finance roles at Bayer HealthCare and for over 20 years at E.I. DuPont.

Mr. Bihl is a director and chairman of the board of Spectral Medical, Inc. (TSX: EDTXF), a Canadian company that develops products for the diagnosis and treatment of severe sepsis and septic shock. Mr. Bihl served as a member of the Board of Directors of Nuvectra Corporation (OTC: NVTRQ) from March 2016 to May 2020. Prior to March 2016 Mr. Bihl served on the Board of Directors of Integer Holdings Corporation (NYSE: ITGR) before it spun off Nuvectra. The Board believes that Mr. Bihl is well qualified to serve on Meridian’s Board due to his 30 years of experience in the medical device industry in operations, finance and general management roles.

The Board has determined that Mr. Bihl is an independent director in accordance with guidelines that the Company has adopted, which comply with the listing standards set forth by the Nasdaq Stock Market. There is no arrangement or understanding between Mr. Bihl and any other person pursuant to which he was elected. There are no transactions in which he has an interest requiring disclosure under Item 404(a) of Regulation S-K. Pursuant to its 2012 Stock Incentive Plan, on July 28, 2020 the Company granted Mr. Bihl options to purchase 40,000 shares of common stock and 20,000 restricted share units. Mr. Bihl will participate in the compensation arrangements for non-employee directors of the Company as described under the heading “Director Compensation” on page 30 in the Company’s proxy statement filed with the SEC on December 18, 2019.

The press release issued by the Company on July 28, 2020 related to Mr. Bihl’s election is furnished herewith as Exhibit 99.1.


Item 9.01.

Financial Statements and Exhibits.





99.1    Press Release dated July 28, 2020
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)


Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: July 28, 2020     By:  

/s/ Bryan T. Baldasare

      Executive Vice President and Chief Financial Officer
      (Principal Financial and Accounting Officer)

Exhibit 99.1



For Immediate Release

Meridian Bioscience Announces New Board Member - Anthony Bihl

CINCINNATI, July 28, 2020 (GLOBE NEWSWIRE) – Meridian Bioscience, Inc. (NASDAQ: VIVO) announces the appointment of Anthony Bihl III to its Board of Directors, effective immediately.

“We welcome Tony to the board as a new independent director and look forward to the leadership he will bring,” said David Phillips, Chairman of Meridian Bioscience. “We were looking to add diagnostics expertise to the board and Tony additionally brings the breadth of leading both large and small public organizations.”

Bihl graduated with distinction from Pennsylvania State University and brings 35 years of leadership experience in global medical device markets, most notably in the diagnostics market. His diagnostics experience began with a broad range of operations and financial roles at Dupont, followed by senior executive roles at Bayer Healthcare’s Diagnostics Division which subsequently led to his becoming CEO of Siemens Medical Solutions Diagnostics, after orchestrating the divestiture to Siemens AG. He joins Meridian’s Board after his retirement in April as CEO and Member of the Board of Managers at Bioventus, LLC. Prior to Bioventus, he served as CEO of American Medical Systems, Inc. Bihl will continue to serve on the boards of Sonendo Inc., Spectral Medical Inc., and the Arthritis Foundation.

“Meridian was an early pioneer in gastrointestinal diagnostics and has stayed true to those roots,” said Bihl. “I have been following their turnaround under Jack Kenny’s leadership and look forward to working with him and the rest of the board as the growth story continues.”

For more information on Meridian, please visit www.meridianbioscience.com.

About Meridian Bioscience, Inc.

Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.

Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is www.meridianbioscience.com.


Charlie Wood

Vice President – Investor Relations

Meridian Bioscience, Inc.

Phone: +1 513.271.3700

Email: mbi@meridianbioscience.com


Document and Entity Information
Jul. 28, 2020
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0000794172
Document Type 8-K
Document Period End Date Jul. 28, 2020
Entity Incorporation State Country Code OH
Entity File Number 0-14902
Entity Tax Identification Number 31-0888197
Entity Address, Address Line One 3471 River Hills Drive
Entity Address, City or Town Cincinnati
Entity Address, State or Province OH
Entity Address, Postal Zip Code 45244
City Area Code (513)
Local Phone Number 271-3700
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, no par value
Trading Symbol VIVO
Security Exchange Name NASDAQ
Entity Emerging Growth Company false